uoc pathology lab spring 2011

8/6/2019 UOC Pathology LAB Spring 2011

1/183

MD PhD

, , 2011


2/183

:

Gastrointestinal system


3/183

1CASE 1

GASTRIC CANCER


4/183

CASE 1

GASTRIC CARCINOMAA


5/183

CASE 1

GASTRIC CARCINOMAB


6/183

CASE 1

GASTRIC CARCINOMAC


7/183

2 CROHNCASE 2

CROHN DISEASE


8/183

CASE 2

CROHN DISEASEA


9/183

CASE 2

CROHN DISEASEB


10/183

CASE 2

CROHN DISEASEC


11/183

CASE 2

CROHN DISEASED


12/183

3CASE 3

ULCERATIVE COLITIS


13/183

CASE 3

ULCERATIVE COLITISA


14/183

CASE 3

ULCERATIVE COLITISB


15/183

CASE 3

ULCERATIVE COLITISC


16/183

4 CASE 4

COLON ADENOMA


17/183

CASE 4

COLON ADENOMAA


18/183

CASE 4

COLON ADENOMAB


19/183

CASE 4

COLON ADENOMAC


20/183

5 CASE 5

COLON CARCINOMA


21/183

CASE 5

COLON CARCINOMAA


22/183

CASE 5

COLON CARCINOMAB


23/183

CASE 5

COLON CARCINOMAC


24/183

6

KCASE 6

CIRRHOSIS


25/183

CASE 6

CIRRHOSISA


26/183

CASE 6

CIRRHOSISB


27/183

CASE 6

CIRRHOSISC


28/183

7

CASE 7

HEPATOCELLULAR

CARCINOMA


29/183

CASE 7

HEPATOCELLULAR

CARCINOMA

A


30/183

CASE 7

HEPATOCELLULAR

CARCINOMA

B


31/183

CASE 7

HEPATOCELLULAR

CARCINOMA

C


32/183

:

-Wingo PA et al.: Long-term trends in cancer in the United States, 1930-1988.

Cancer 97:3133, 2003.-Sands BE: Inflammatory bowel disease: past, present, and future.Journal of Gastroenterology 42:16,2007.

-Jean Marx, et al. BIOMEDICINE: Puzzling Out the Pains in the Gut

Science 315, 33, 2007.

-Su L et al.: Targeted epithelial tight junction dysfunction causes

immune activation and contributes to development of experimental colitis.Gastroenterology 136:551, 2009.

-Shen L et al.: Integrated genetic and epigenetic analysis identifies

three different subclasses of colon cancer.PNAS 104:18654, 2007.

-Hahn W, Weinberg R: Rules for making cancer cells.

New England Journal of Medicine 347:1593, 2002.-Wood LD et al: The genomic landscapes of human breast and colorectal cancers

Science, 318(5853):1108, 2007.

-Schuppan D, Afdhal NH: Liver cirrhosis.

Lancet 371:838, 2008.

-Llovet JM et al.: Design and endpoints of clinical trials in hepatocellular carcinoma

New England Journal of Medicine 359:378, 2008.


33/183

:

Respiratory system


34/183

1

CASE 1

LUNG SQUAMOUS CELLCARCINOMA


35/183

CASE 1

SQUAMOUS CELL CARCINOMAA


36/183

BCASE 1SQUAMOUS CELL CARCINOMA


37/183

CCASE 1SQUAMOUS CELL CARCINOMA


38/183

2

CASE 2

Lung adenocarcinoma


39/183

CASE 2

Lung adenocarcinomaA


40/183

BCASE 2Lung adenocarcinoma


41/183

CCASE 2Lung adenocarcinoma


42/183

3

CASE 3

SMALL CELL CARCINOMA


43/183

CASE 3

SMALL CELL CARCINOMAA


44/183

BCASE 3SMALL CELL CARCINOMA

C S 3


45/183

CCASE 3SMALL CELL CARCINOMA


46/183

4

CASE 4

MESOTHELIOMA

CASE 4


47/183

CASE 4

MESOTHELIOMAA

CASE 4


48/183

CASE 4MESOTHELIOMA


49/183

:

-Jemal A et al.: Cancer statistics, 2008.

CA Caner J Clin 58:71, 2008.-Hoffmann D. et al.:The biologic significance of tobacco-specific N-nitrosamines:Smoking and adenocarcinoma of the lung.

Critical Reviews in Toxicology 26:199, 1996.

-el-Tokry M et al.: Significant changes in the distribution of histologic types

of lung cancer.: a review of 4928 cases.

Cancer 65:2361, 1990.-Pershagen G. et al.: Residential radon exposure and lung cancer in Sweden.New England Journal of Medicine 330:159, 1994.

-Herbst RS et al.: Molecular origins of cancer: Lung Cancer.


-Patel AM et al: Paraneoplastic syndromes associated with lung cancer.

Annual Reviews in Medicine 54:73, 2003.-Greillier L, Astoul P: Mesothelioma and asbestos-related pleural diseases.Respiration 76:1, 2008.

-Rivera Z et al.: The relationship between simian virus 40 and mesothelioma.Current Opinion in Pulmonary Medicine 14:316, 2008.


50/183

:

-

Genitourinary system


51/183

1

CASE 1

RENAL

CLEAR CELL CARCINOMA

CASE 1


52/183

CASE 1

RENAL CLEAR CELL CARCINOMA

CASE 1


53/183

CASE 1

RENAL CLEAR CELL CARCINOMA

CCASE 1


54/183

CCASE 1RENAL CLEAR CELL CARCINOMA

CCASE 1


55/183

CCASE 1RENAL CLEAR CELL CARCINOMA


56/183

2

CASE 2

LOW GRADETRANSITIONAL CELL CARCINOMA

CASE 2 A


57/183

CASE 2

Low grade transitional cell carcinomaA

BCASE 2


58/183

BCASE 2Low grade transitional cell carcinoma

CCASE 2


59/183

CCASE 2Low grade transitional cell carcinoma


60/183

3

CASE 3

HIGH GRADETRANSITIONAL CELL CARCINOMA

ACASE 3


61/183

ACASE 3High grade transitional cell carcinoma

CASE 3


62/183

CASE 3High grade transitional cell carcinoma

CCASE 3


63/183

CCASE 3High grade transitional cell carcinoma


64/183

4

CASE 4

SEMINOMA

CASE 4 A


65/183

CASE 4

SEMINOMAA

BCASE 4


66/183

BCASE 4SEMINOMA

CCASE 4


67/183

CCASE 4SEMINOMA


68/183

5

CASE 5

TESTIS TERATOMA

ACASE 5


69/183

ACASE 5TESTIS TERATOMA

BCASE 5


70/183

BTESTIS TERATOMA

CCASE 5


71/183

CTESTIS TERATOCARCINOMA


72/183

6

CASE 6

LOW GRADEPROSTATE CARCINOMA

ACASE 6


73/183

ALOW GRADE PROSTATE CARCINOMA

BCASE 6


74/183

BLOW GRADE PROSTATE CARCINOMA


75/183

7

CASE 7

HIGH GRADEPROSTATE CARCINOMA


76/183

CASE 7


77/183

HIGH GRADE PROSTATE CARCINOMA

CCASE 7


78/183

CHIGH GRADE PROSTATE CARCINOMA


79/183

:

-Cohen HT, McGovern FJ.: Renal cell carcinoma.


-Eble JN et al.: The World Health Organization classification of tumors of the urinarysystem and male genital system.

Lyon, IARC Press, 2004.

-Epstein JI et al.: The World Health Organization/International Society

of Urotogical Pathology consencus classification of urothelial (transitional cell)

neoplasms of the urinary bladder.

Americal Journal of Surgical Pathology 22:1435, 1998.

-Bosl GJ, Motzer RJ.: Testicular germ cell cancer.


-Nelson WG et al.: Prostate cancer.


-Kumar-Sinha C, et al: Recurrent gene fusions in prostate cancer.

Nature Reviews Cancer 8:497, 2008.


80/183

:

-

Breast-gynecological system


81/183

1

CASE 1

ENDOMETRIAL CARCINOMA


82/183

CASE 1

E d t i l C i


83/183

Endometrial Carcinoma


84/183

2

CASE 2

SIMPLE

ENDOMETRIAL HYPERPLASIA

CASE 2

Si l E d t i l H l iA


85/183

Simple Endometrial HyperplasiaA

BCASE 2Si l E d t i l H l i


86/183

BSimple Endometrial Hyperplasia


87/183

3

CASE 3

COMPLEX ENDOMETRIAL

HEPERPLASIA

ACASE 2C l E d t i l H l i


88/183

Complex Endometrial Hyperplasia

BCASE 2C l E d t i l H l i


89/183


DCASE 2C l E d t i l H l i


90/183



91/183

4

CASE 4

SEROUSCYSTADENOCARCINOMA

OF THE OVARI

CASE 4

Ovarian Serous CarcinomaA


92/183

Ovarian Serous Carcinoma

CASE 4Ovarian Serous Carcinoma


93/183


CASE 4

Ovarian Serous CarcinomaC


94/183



95/183

5

CASE 5

UTERINE LEIOMYOMA

ACASE 5Uterine Leiomyoma


96/183

Uterine Leiomyoma

CASE 5Uterine Leiomyoma


97/183

Uterine Leiomyoma


98/183

ACASE 6High Grade CIN


99/183

High Grade CIN

CASE 6High Grade CIN


100/183

High Grade CIN


101/183

7

CASE 7

FIBROCYSTIC DISEASE

OF THE BREAST


102/183


103/183


104/183


105/183


106/183

CASE 8Breast Papilloma


107/183

Breast Papilloma


108/183

9

CASE 9

DUCTAL BREAST CARCINOMA


109/183

CCASE 9Ductal Breast Carcinoma


110/183

DCASE 9Ductal Breast Carcinoma


111/183


112/183

10

CASE 10

LOBULAR BREAST CARCINOMA

ACASE 10Lobular Breast Carcinoma


113/183

BCASE 10Lobular Breast Carcinoma


114/183


115/183

:


116/183

-Schiffman M et al.: Human papillomavirus and cervical cancer.

Lancet, 370:890, 2007.-Cutts PT et al.: Human papillomavirus and HPV vaccines: a review.

Bull World Health Organization 85:719, 2007.

-Di Cristofano A, Elllenson LH: Endometrial carcinoma.Annual Review in Pathology 2:57, 2007.

-Ligon AH, Morton CC: Leiomyomata: treatabllity and cytogenetic studies.Human Reproduction update 7:8, 2008.

-Bell DA: Origins and molecular pathology of ovarian cancer.

Modern Pathology, 18:S19, 2005.

-Stingl J, Caldas C: Molecular heterogeneity of breast carcinomas and the cancer

stem cell hypothesis.


-Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer.

New England Journal of Medicine 354:270, 2006.-Burstein HJ et al.: Ductal carcinoma in situ of the breast.



117/183

:

Lymphoid system


118/183

1

/ -

CASE 1

SMALL LYMPHOCYTIC

LYMPHOMA/LEUKEMIA

CASE 1

SMALL LYMPOCYTIC LYMPHOMA/LEUKEMIAA


119/183

CCASE 1SMALL LYMPOCYTIC LYMPHOMA/LEUKEMIA


120/183


121/183

2

() CASE 2

FOLLICULAR LYMPHOMA


122/183

CASE 2FOLLICULAR LYMPHOMA


123/183


124/183

BCASE 3DIFFUSE LARGE B-CELL LYMHOMA


125/183


126/183

4

HODGKINCASE 4

CLASSICAL

HODGKIN LYMPHOMA


127/183

CASE 4CLASSICAL HODGKIN LYMPHOMA


128/183

CCASE 4CLASSICAL HODGKIN LYMPHOMA


129/183

:


130/183

:

-Mebius DP: Organogenesis of lymphoid tissues.Nature Reviews Immunology 3:292, 2003.

-Harris NL. et al.: World Health Organization classification of neoplastic diseasesof the hematopoietic and lymphoid tissues:

Report of the Clinical Advisory Committee meeting-Airlie House,

Virginia, November 1997.

Journal of Clinical Oncology 17:3835, 1999.

-Tsimberidou AM, Keating MJ: Richters transformation in chroniclymphocytic leukemia.Seminars in Oncology 33:250, 2006.

-Kuppers R.: Prognosis in follicular lymphoma- its in the microenviroment.


-Re D et al.: Molecular pathogenesis of Hodgkins lymphoma .

Journal of Clinical Oncology 237:6379, 2005.


131/183


132/183

ACASE 1Squamous Cell Carcinoma


133/183

CASE 1

Squamous Cell CarcinomaB


134/183

CCASE 1Squamous Cell Carcinoma


135/183


136/183

2

CASE 2

BASAL CELL CARCINOMA


137/183


138/183


139/183

3

CASE 3

MELANOCYTIC NEVUS

ACASE 3Melanocytic Nevus


140/183


141/183

CCASE 3Melanocytic Nevus


142/183


143/183

CASE 4

MelanomaA


144/183

CASE 4Melanoma


145/183


146/183

5

CASE 5

LEIOMYOSARCOMA


147/183

CASE 5Leiomyosarcoma


148/183


149/183

ACASE 6Leiomyoma


150/183


151/183


152/183

ACASE 7Myxoid Liposarcoma


153/183

CASE 7Myxoid Liposarcoma


154/183


155/183

8

CASE 8

SCHWANNOMA

ACASE 8Schwannoma


156/183


157/183

:

P ll k PM t l Hi h f f BRAF t ti i i


158/183

-Pollock PM et al.: High frequency of BRAF mutations in nevi.Nature Genetics 33:19, 2003.

-Chib L: The genetics of malignant melanoma: lessons from mouse and man.Nature Reviews Cancer 3:559, 2003.

-Rubin AI et al.: Basal-cell carcinoma.New England Journal of Medicine 353:2262, 2005.

-Alam M, Ratner D: Cutaneous squamous-cell carcinoma.New England Journal of Medicine 344:975, 2001.

-Mitelman F et al.: The impact of translocations and gene fusions on cancer causation.Nature Reviews Cancer 7:233, 2007.

-Riggi N et al.: Sarcomas: genetics, signaling, and cellular origins.Part I:

The fellowship of TET.

Journal of Pathology 213:4, 2007.


159/183

: -

CNS- Endocrine system


160/183

1

CASE 1MENINGIOMA

ACASE 1Meningioma


161/183

CASE 1

Meningioma


162/183

CCASE 1Meningioma


163/183


164/183

2

CASE 2

LOW GRADE

GLIOMA

CASE 2

Low Grade GliomaA


165/183


166/183


167/183


168/183

CASE 2High Grade Glioma


169/183


170/183

4

CASE 4

NODULAR GOITER

CASE 4

Nodular GoiterA


171/183


172/183


173/183

5

CASE 5

LYMPHOCYTIC THYROIDITIS

(HASHIMOTO)

ACASE 5Lymphocytic Thyroiditis


174/183

CASE 5Lymphocytic Thyroiditis


175/183


176/183

6

CASE 6

THYROID

PAPILLARY CARCINOMA

ACASE 6Thyroid Papillary Carcinoma


177/183

CASE 6Thyroid Papillary Cell Carcinoma


178/183


179/183

7

CASE 7

THYROID

FOLLICULAR CARCINOMA

ACASE 7Thyroid Follicular Carcinoma


180/183

BCASE 7Thyroid Follicular Carcinoma


181/183

CCASE 7Thyroid Follicular Carcinoma


182/183

:


183/183

-The cancer genome atlas research network. Comprehensive genomicCharacterization defines human glioblastoma genes and core pathways .

Nature 455:1061, 2008.

-Mellinghoff IK et al.: Molecular determinants of the response of glioblastomas to

EGFR kinase inhibitors.New England Journal of Medicine 353:2012, 2005.

-Singh SK et al.: Identification of a cancer stem cell in human brain tumors.Cancer Research 63:5821, 2003.

-McLachlan SM et al.: The link between Graves disease and Hashimotos thyroiditis:

A role for regulatory T cells.

Endocrinlogy 148:5724, 2007.

-Kondo T et al.: Pathogenetic mechanisms in thyroid follicular-cell neoplasia.


uoc pathology lab spring 2011

Documents